How Much Does Ozempic Cost in Tennessee in 2026?

Ozempic Retail Pricing Across Tennessee

The cash price for a one-month supply of Ozempic at Tennessee retail pharmacies averages $998, matching the Novo Nordisk wholesale acquisition cost. That number holds whether you fill at a chain in Nashville, a Walgreens in Memphis, or an independent pharmacy in Knoxville. Price variation between pharmacies is minimal because the drug is single-source branded.

Why the Sticker Price Stays High

Semaglutide injection (brand name Ozempic) has no FDA-approved generic equivalent. Novo Nordisk sets the list price, and pharmacies pass it through with a dispensing margin that rarely moves the total by more than $10 to $20. The SUSTAIN trial program demonstrated significant HbA1c reductions and cardiovascular benefit [1], which drove demand well beyond manufacturing capacity for parts of 2023 and 2024. Supply has stabilized in 2026, but pricing has not dropped.

Comparing Cash Prices to National Averages

Tennessee's $998 average mirrors the national median. States with aggressive Medicaid preferred-drug-list negotiations (New York, California) sometimes see slightly lower effective prices for insured patients, but the cash sticker is uniform. If your pharmacy quotes a figure above $1,050, request a price match or check GoodRx, RxSaver, or Amazon Pharmacy for a coupon that may trim $20 to $80 off the retail total.

Tennessee Medicaid (TennCare) Coverage

TennCare covers Ozempic for enrollees with a documented type 2 diabetes diagnosis. It does not cover Ozempic prescribed off-label for weight management alone. This distinction matters because an estimated 36.5% of Tennessee adults meet the CDC definition of obesity [2], yet the Medicaid pathway to GLP-1 therapy is restricted to glycemic control.

Qualifying for TennCare Coverage

To receive Ozempic through TennCare, a prescriber must submit prior authorization confirming a type 2 diabetes diagnosis (ICD-10 E11.x), a recent HbA1c value, and documented failure or contraindication to metformin. TennCare's preferred drug list typically requires step therapy: metformin first, then a sulfonylurea or SGLT2 inhibitor, before approving a GLP-1 receptor agonist.

What Happens if You Need It for Weight Loss

Patients seeking semaglutide specifically for weight management should know that the FDA-approved weight-loss formulation is Wegovy (semaglutide 2.4 mg), not Ozempic. TennCare does not cover Wegovy for obesity as of mid-2026. Commercially insured patients or those willing to pay cash have more options, including compounded semaglutide (discussed below).

Commercial Insurance Coverage in Tennessee

Most major commercial insurers operating in Tennessee, including BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna, include Ozempic on their formularies for type 2 diabetes. Coverage for weight management varies plan by plan.

Prior Authorization Requirements

Nearly every Tennessee commercial plan requires prior authorization for Ozempic. The typical approval criteria mirror TennCare's: confirmed type 2 diabetes, HbA1c at or above 7.0%, and trial of at least one first-line oral agent. Some plans require two oral agents to have failed. Approval letters usually last 12 months before renewal.

Copay Ranges by Plan Tier

If Ozempic sits on a plan's preferred brand tier, Tennessee patients generally pay $30 to $75 per fill. Non-preferred placement pushes copays to $100 to $200. High-deductible health plans may require full cash price until the deductible is met, at which point coinsurance (often 20% to 30%) applies. A 30% coinsurance on $998 is roughly $300, still a significant monthly expense.

Employer-Sponsored Plans

Large self-insured employers in Tennessee (FedEx, HCA Healthcare, Nissan North America) often negotiate separate pharmacy benefit contracts. Coverage terms can differ substantially from the insurer's standard formulary. Ask your HR benefits coordinator for the specific step-therapy requirements and copay tier rather than relying on the insurer's public formulary document.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card that reduces the out-of-pocket cost of Ozempic for commercially insured patients. The card is not available to patients enrolled in any government program, including Medicare, Medicaid, Tricare, or VA benefits [3].

How It Works in Tennessee

Eligible patients register at the Novo Nordisk patient assistance website or receive activation through their prescriber's office. The card applies at the pharmacy counter and may bring the copay down to $25 per 28-day supply for up to 24 months. There is a maximum monthly benefit cap (typically $150 to $300 off the copay), which means patients with very high coinsurance may still pay a residual balance.

Limitations to Watch

The card resets annually and requires re-enrollment. If your insurance plan changes, particularly during open enrollment season each November, verify that the card still applies. Patients who lose commercial coverage and move to a government plan become ineligible immediately. The savings card also does not apply at every pharmacy; confirm acceptance before transferring your prescription.

Compounded Semaglutide in Tennessee

Compounded semaglutide is available through licensed 503A compounding pharmacies in Tennessee at approximately $199 per month. That price point, roughly 80% below brand Ozempic, has made compounded versions popular among cash-pay patients.

Legal Status in Tennessee

Tennessee permits 503A compounding pharmacies to prepare patient-specific prescriptions of semaglutide when a licensed prescriber writes an individualized order. The Tennessee Board of Pharmacy oversees these facilities. Federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) allows compounding of drugs that are not "essentially a copy" of a commercially available product when certain conditions are met [4].

FDA Shortage List and Its Impact

The FDA maintained semaglutide on its drug shortage list from March 2023 through early 2025, which expanded legal compounding latitude. As of 2026, the shortage status has been resolved for most dosage forms. Compounding pharmacies may still prepare semaglutide under 503A rules with a valid patient-specific prescription, but the regulatory environment could shift. Patients using compounded semaglutide should confirm their pharmacy holds a current Tennessee Board of Pharmacy license and uses USP 797-compliant sterile compounding practices.

Quality Considerations

Not all compounded semaglutide is equivalent. The FDA issued warning letters in 2023 and 2024 to multiple compounding pharmacies nationwide for potency deviations and sterility failures [5]. Tennessee patients should verify that their pharmacy participates in third-party potency testing, uses pharmaceutical-grade semaglutide base, and provides certificates of analysis on request. Price alone should not guide this decision.

Telehealth Access to Ozempic in Tennessee

Tennessee law permits telehealth prescribing of Ozempic with a valid prescriber-patient relationship. Several national telehealth platforms operate in the state and can prescribe semaglutide after a video or audio evaluation.

How Tennessee Telehealth Prescribing Works

The Tennessee Board of Medical Examiners requires that a prescriber establish a legitimate medical relationship before issuing a controlled or non-controlled prescription via telehealth. GLP-1 receptor agonists like semaglutide are not classified as controlled substances, which simplifies the process. A physician, nurse practitioner, or physician assistant licensed in Tennessee can evaluate the patient remotely, review labs, and transmit the prescription electronically to any Tennessee pharmacy.

Cost Through Telehealth Platforms

Telehealth consultation fees for GLP-1 prescriptions in Tennessee range from $50 to $199 per visit. Some platforms bundle the consultation, prescription, and compounded medication into a single monthly price ($199 to $399). Patients using brand Ozempic through telehealth still face the $998 pharmacy price unless insurance or the Novo Nordisk savings card applies. Telehealth does not change the drug's cost; it changes the access pathway.

Strategies to Lower Your Ozempic Cost in Tennessee

Bringing Ozempic's price below $998 in Tennessee requires combining multiple approaches. No single program eliminates the cost entirely for uninsured patients.

Step 1: Check Your Insurance Formulary

Call the number on your insurance card and ask three questions. Is Ozempic on formulary? What tier? What are the prior authorization criteria? Get the answers in writing (most insurers will email or fax a coverage determination). This tells you your baseline cost before applying any discount.

Step 2: Apply the Novo Nordisk Savings Card

If you have commercial insurance, activate the savings card before your first fill. It stacks on top of your insurance benefit and reduces the copay, not the list price. For a patient with a $75 copay, the card may bring it to $25. For a patient with $300 coinsurance, the card subtracts its maximum benefit and leaves a remainder.

Step 3: Explore Patient Assistance Programs

Novo Nordisk operates a Patient Assistance Program (PAP) for uninsured patients with household income below 400% of the federal poverty level. In 2026, that threshold is approximately $62,400 for a single-person household [6]. Approved applicants receive Ozempic at no cost, shipped directly to the prescriber's office or the patient's home. The application requires income documentation, a prescription, and a prescriber signature.

Step 4: Compare Compounded Semaglutide

For patients who do not qualify for PAP and lack insurance coverage, compounded semaglutide at $199 per month through a Tennessee-licensed 503A pharmacy represents the lowest-cost injectable option. Discuss this alternative with your prescriber. The dose, injection frequency, and titration schedule should match FDA-approved protocols even when using a compounded formulation.

Step 5: Consider Oral Semaglutide (Rybelsus)

Rybelsus (oral semaglutide, 7 mg and 14 mg tablets) treats type 2 diabetes and carries a list price lower than injectable Ozempic in some pharmacy benefit designs. Tennessee patients whose primary goal is glycemic control, not weight loss, may find better formulary placement with Rybelsus. The PIONEER trial program demonstrated HbA1c reductions of 1.0% to 1.4% with oral semaglutide 14 mg [7].

Clinical Context: Why Semaglutide Costs What It Does

Ozempic's pricing reflects its clinical profile. The SUSTAIN-7 trial (N=1,201) showed that semaglutide 0.5 mg reduced HbA1c by 1.5% and body weight by 4.6 kg at 40 weeks, while semaglutide 1.0 mg reduced HbA1c by 1.8% and body weight by 6.5 kg, both significantly greater than dulaglutide at corresponding doses [1].

Cardiovascular Benefit

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease but without diabetes [8]. Dr. A. Michael Lincoff, the trial's principal investigator, stated: "This is the first trial to show that a weight-management medication can reduce cardiovascular events in a population selected for cardiovascular risk" [8]. That finding reshaped payer willingness to cover GLP-1 therapy, though Tennessee Medicaid has not yet expanded its coverage criteria in response.

Cost-Effectiveness Analyses

The Institute for Clinical and Economic Review (ICER) estimated in 2024 that semaglutide for obesity would need to be priced between $7,500 and $9,800 per year to meet conventional cost-effectiveness thresholds [9]. At $998 per month ($11,976 per year), brand Ozempic exceeds that range. This gap partly explains why public payers like TennCare restrict coverage to diabetes-only indications, where the cost-effectiveness ratio is more favorable due to avoided downstream complications (dialysis, amputation, retinopathy).

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk, citing "high-level evidence for cardiovascular benefit" [10].

Tennessee-Specific Pharmacy and Regulatory Notes

Tennessee has no state-level drug pricing transparency law comparable to those in Colorado or Oregon. Pharmacy benefit managers (PBMs) operating in the state are not required to disclose rebate pass-through rates to patients. This means the net price that insurers pay for Ozempic after rebates may be 40% to 60% below list price, but those savings do not always reach the patient's copay calculation.

Rural Access Considerations

Tennessee's rural counties (particularly in Appalachian East Tennessee and the Delta region) have fewer retail pharmacies and limited specialty pharmacy access. Patients in these areas may need to use mail-order pharmacy or telehealth-to-home-delivery services to obtain Ozempic without driving 60 or more miles. Express Scripts, CVS Caremark, and OptumRx all deliver to Tennessee addresses with standard shipping at no additional pharmacy charge.

State Legislative Watch

Tennessee House Bill 1032 (2025 session) proposed requiring TennCare to cover FDA-approved anti-obesity medications, including GLP-1 receptor agonists, for BMI at or above 30. The bill did not advance past committee. Similar legislation may be reintroduced in the 2027 session. Patients and advocacy groups tracking this issue can monitor bill status through the Tennessee General Assembly website.